Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity
Compared with placebo, both TZP 15 mg and 10 mg QW are cost-effective options for individuals with T2D and comorbid obesity.
Authors
- Debra Winberg (ORCID: https://orcid.org/0000-0003-2909-1455)
- Vivian Fonseca (ORCID: https://orcid.org/0000-0002-3381-7151)
- Dawei Guan (ORCID: https://orcid.org/0009-0004-2341-940X)
- Tiange Tang
- Lizheng Shi (ORCID: https://orcid.org/0000-0002-7827-6766)
- Hui Shao (ORCID: https://orcid.org/0000-0002-4088-546X)
- M.‐X. Tang (ORCID: https://orcid.org/0009-0002-0267-110X)
Institutions
- Tulane University (US)
- University of Florida (US)
- Georgia Department of Public Health (US)
- Florida College (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1111/dom.16466
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88